Company profile: Protagonist Therapeutics
1.1 - Company Overview
Company description
- Provider of orally-stable peptide therapeutics to treat diseases currently addressed by injectable antibodies.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Protagonist Therapeutics
Corpak MedSystems
HQ: United States
Website
- Description: Provider of enteral feeding and bedside location medical devices, developing, manufacturing, and marketing premium-branded solutions. Portfolio includes the CORTRAK* 2 Enteral Access System for real-time feeding tube placement; MIC-KEY* low-profile G, GJ, and J feeding tubes; the MIC-KEY* Over-the-Wire stoma measuring device; and MIC* PEG kits. Holds a leading position in adult long-term nasogastric feeding tubes.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Corpak MedSystems company profile →
Echosens
HQ: France
Website
- Description: Provider of non-invasive hepatology diagnostics, offering FibroScan devices for assessment of liver fibrosis and steatosis, including Next-Generation FibroScan, FibroScan 630 Expert for liver/spleen stiffness and ultrasound attenuation, and portable FibroScan Compact 530. Solutions include LSM by VCTE for fibrosis and CAP for steatosis, supported by extensive peer-reviewed publications and international guidelines.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Echosens company profile →
Napo Pharmaceuticals
HQ: United States
Website
- Description: Provider of proprietary pharmaceuticals for gastrointestinal indications and insulin-resistant diseases, offering Mytesi (crofelemer) for chronic diarrhea in HIV/AIDS on antiretroviral therapy; NP-300, a drug candidate for moderate to severe infectious diarrhea including cholera; NP-500 for insulin-resistant diseases; CRO-IBS for diarrhea-predominant IBS; and an Investigator-Initiated Trials program on crofelemer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Napo Pharmaceuticals company profile →
Ardelyx
HQ: United States
Website
- Description: Provider of oral therapeutics addressing mineral metabolism and metabolic disorders, including: RDX013, an investigational therapy for hyperkalemia via gut potassium secretion; RDX020, a research program targeting metabolic acidosis by inhibiting intestinal bicarbonate exchange; PHOZEVEL (tenapanor), approved in Japan for hyperphosphatemia; and IBSRELA (tenapanor), available in Canada for IBS-C.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ardelyx company profile →
CapsoVision
HQ: United States
Website
- Description: Provider of capsule endoscopy solutions and healthcare-focused medical devices, from a global innovator specializing in capsule endoscopy, medical device, and healthcare.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CapsoVision company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Protagonist Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Protagonist Therapeutics
2.2 - Growth funds investing in similar companies to Protagonist Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Protagonist Therapeutics
4.2 - Public trading comparable groups for Protagonist Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →